MEMPHIS, Tenn.--(BUSINESS WIRE)--Medtronic, Inc. (NYSE:MDT) announced today that the U.S. Food and Drug Administration (FDA) has granted an investigational device exemption (IDE) to conduct a clinical trial to study INFUSE(r) Bone Graft in a cervical spinal fusion. The investigational device will consist of INFUSE Bone Graft inside a polyetheretherketone (PEEK) polymer interbody spacer used with an anterior cervical plate as a method of facilitating spinal fusion. The goal of the clinical trial is to evaluate whether INFUSE Bone Graft is a safe and effective alternative to traditional bone grafting techniques for cervical spine fusions.
